Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q35775241)
Watch
English
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.
scientific article published on 23 April 2015
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMCID
4478974
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908604%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
title
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors
(English)
1 reference
stated in
Europe PubMed Central
PMCID
4478974
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908604%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
author
Udai Banerji
series ordinal
4
1 reference
stated in
Europe PubMed Central
PMCID
4478974
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908604%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
author name string
A Stewart
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMCID
4478974
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908604%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
P Thavasu
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMCID
4478974
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908604%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
J S de Bono
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMCID
4478974
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908604%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
publication date
23 April 2015
1 reference
stated in
Europe PubMed Central
PMCID
4478974
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908604%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
published in
Annals of Oncology
1 reference
stated in
Europe PubMed Central
PMCID
4478974
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908604%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
volume
26
1 reference
stated in
Europe PubMed Central
PMCID
4478974
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908604%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
page(s)
1504-1510
1 reference
stated in
Europe PubMed Central
PMCID
4478974
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908604%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
issue
7
1 reference
stated in
Europe PubMed Central
PMCID
4478974
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908604%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
cites work
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
27 July 2018
Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
27 July 2018
Development of therapeutic combinations targeting major cancer signaling pathways
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
27 July 2018
Intratumor heterogeneity: evolution through space and time
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
27 July 2018
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
27 July 2018
Combinatorial drug therapy for cancer in the post-genomic era.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
27 July 2018
Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
27 July 2018
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
27 July 2018
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
27 July 2018
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
27 July 2018
Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
27 July 2018
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
27 July 2018
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
27 July 2018
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
27 July 2018
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
27 July 2018
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
27 July 2018
Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
27 July 2018
Antitumor activity in RAS-driven tumors by blocking AKT and MEK.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
25 September 2018
Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
25 September 2018
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
25 September 2018
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
25 September 2018
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
25 September 2018
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
25 September 2018
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
25 September 2018
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4478974
retrieved
25 September 2018
Identifiers
DOI
10.1093/ANNONC/MDV188
1 reference
stated in
Europe PubMed Central
PMCID
4478974
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908604%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
PMCID
4478974
1 reference
stated in
Europe PubMed Central
PMCID
4478974
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908604%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
PubMed ID
25908604
1 reference
stated in
Europe PubMed Central
PMCID
4478974
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908604%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
ResearchGate publication ID
275356428
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
